Exportal for children, 5 g 6 pcs

In the large intestine lactitol is broken down by intestinal flora into low molecular weight organic acids which leads to increase of osmotic pressure in the large intestine, increase of stool volume, its softening, facilitation of defecation and normalization of bowel function.

The laxative effect usually occurs within 24 hours after using the drug (delayed by the passage of the drug through the gastrointestinal tract). At the beginning of the course of treatment, the laxative action of the drug may be delayed; the effect may come on the second or third day of its use.

In patients with hepatic encephalopathy or hepatic coma (or precoma) the effect is achieved due to migration of ammonia from blood into the large intestine (due to lower pH, increase osmotic pressure in the intestinal lumen), removal of trapped ammonium ions and other nitrogen-containing toxic substances from the large intestine.

Lactitol suppresses proteolytic bacteria and increases the number of acidophilic bacteria, thus restoring the microbiome.

Pharmacokinetics.

Lactitol exerts its effect only in the large intestine, where it reaches completely after ingestion. It is absorbed in minimal amounts in unchanged form (not more than 0.5 – 2% of the dose taken).

Indications

Constipation, the need to regulate stool for medical purposes (bowel cleansing in preparation for endoscopic and radiological studies, surgical interventions on the rectum, anal sphincter and the area adjacent to it), intestinal dysbacteriosis. Hepatic encephalopathy, hepatic precoma and coma, hyperammonemia.

Active ingredient

Lactitol

Composition

Lactitol monohydrate – 5 g or 10 g in a sachet, 200 g or 500 g in plastic containers. Without excipients.

How to take, the dosage

Ingestion with meals, mixed with various drinks (water, tea, coffee, juices, etc.) or liquid foods.

In constipation and dysbacteriosis. The drug should be taken once, the entire daily dose at once, in one sitting.

Children 1 -6 years old -2.5 – 5 g (1/2 – 1 teaspoon of powder) per day.

Children 6 -12 years -5 – 10 g (1 – 2 teaspoons of powder) per day.

Children 12 -16 years -10 – 20 g (2 – 4 teaspoons of powder) per day.

Adults: 20 g (4 teaspoons of powder) per day.

The drug should induce stools once a day; after a steady laxative effect has occurred over several days of use, the dose may be reduced. In some cases half the recommended daily dose may be enough to have the desired effect:

In children 1-6 years of age 1.25-2.5 g (1/4-1/2 teaspoons of powder) daily.

Children 6-12 years – 2.5 to 5 g (1/2 to 1 teaspoon of powder) per day.

Children 12-16 years – 5 – 10 g (1 – 2 teaspoons of powder) per day.

Adults: 10 g (2 teaspoons of powder) per day.

The minimum course of therapy after which it is necessary to consult a physician is 5 months. It is recommended to use the drug in children under the supervision of a doctor.

In the regulation of stools for medical purposes. Take 20 g of the drug diluted in 1 liter of water three times (at 12, 15 and 18 hours) on the eve of medical procedures.

In hepatic encephalopathy, hepatic precoma and coma, hyperammonemia. The dose of the drug should be chosen individually for each patient, depending on the degree of severity of the disease and the individual response to the drug. Initial daily dose is usually 0.5-0.7 g per 1 kg of body weight. This dose is divided into three single doses. It is taken with meals. A dose that causes two “soft” stools per day should be chosen.

Interaction

When taking Exportal® concomitantly with intestinal pH-dependent release drugs, note that lactitol lowers intestinal pH.

The use of Exportal® within two hours of taking other medications is not recommended.

Special Instructions

Lactitol has a low caloric value (2 kcal/g), does not affect blood glucose levels and can be used in diabetic patients.

Higher fluid intake is advisable during the entire course of application of the drug.

The use of Exportal® has no effect on psychomotor functions associated with driving or operating machinery and equipment

Synopsis

White crystalline powder

Contraindications

• High sensitivity to lactitol.
• Lactase deficiency, fructose and galactose intolerance, galactosemia, glucose-galactose malabsorption syndrome.
• Syndrome of complete or partial intestinal obstruction, suspected organic damage to the gastrointestinal tract, abdominal pain and rectal bleeding of unclear genesis, inflammatory bowel disease (rectocolitis, regional enteritis), previous water-salt imbalance.
• Children under 1 year

.

Side effects

At the beginning of treatment a feeling of discomfort in the abdomen, flatulence and, in rare cases, abdominal pain and bloating may occur. These phenomena usually disappear with continued use of the drug as it is adapted to it.

If high doses are used for a long time while treating hepatic encephalopathy, the patient may develop electrolyte imbalance due to diarrhea.

Because of individual differences, some patients may have diarrhea even when taking the recommended dose of the drug. In this case, the dose of the drug should be reduced.

The incidence of side effects is classified according to the recommendations of the World Health Organization: very common – at least 10%; common – at least 1%, but less than 10%; infrequent – at least 0.1%, but less than 1%; rare – at least 0.01%, but less than 0.1%; very rare – less than 0.01%; unknown frequency – cannot be estimated based on available data.

Gastrointestinal disorders

Rare: flatulence, abdominal pain, abdominal bloating, vomiting, diarrhea.

Very rare: nausea, anal itching.

Overdose

Symptoms: diarrhea, abdominal pain, vomiting may occur in rare cases. These phenomena are usually resolved by reducing the dose of the drug.

Treatment: dose reduction or discontinuation of the drug. Correction of possible water-salt balance disorders.

Pregnancy use

Because of the minimal absorption of lactitol, no adverse effects on the woman or the fetus are expected when it is used during pregnancy. The drug can be taken during pregnancy if the potential benefit to the mother exceeds the potential risk to the fetus.

In view of minimal absorption, penetration of lactitol into breast milk is not expected. The drug may be taken during breastfeeding if the potential benefit to the mother exceeds the potential risk to the baby.

Similarities

Exportal